be_ixf;ym_202605 d_05; ct_50
AMEX:URA charts & data provided by TradingView

Latest Insights on URA

It was supposed to be a beautiful day in the neighborhood, but Wall Street was hoping for a little less “beautiful” on the jobs front. Jobs Amassing, Aurora’s Crashing, Uber’s Dashing February 7, 2020 by Joseph Hargett Great Stuff Friday Four Play: The “What Do You Mean, No Rate Cut?” Edition (Did a friend forward you this email? If so, you owe them big-time! Seriously, this is Great Stuff. We don’t take that title lightly. After you’ve thanked your friend profusely, why not sign up for yourself today? It’s mostly painless. I promise.) I […]
More winning in the U.S.-China trade war. Is it time to ’Murica things up around here a little bit? I think it is. China’s Valentine’s Gift; Earnings All a-Twitter February 6, 2020 by Joseph Hargett Great Stuff China’s Valentine’s Day Gift Well color me happy, the market is on a four-day winning streak! Following on the heels of yesterday’s impressive payrolls data, the major market indexes are retesting all-time high territory. Today’s driver was news that China will cut retaliatory tariffs on some U.S. goods in half. What’s more, the adjustments will […]
Today, I want to talk about a few of the most popular investing tools … as well as a brand-new investment strategy that I believe deserves your attention. It’s Time to Upgrade Your Investing Toolbox February 5, 2020 by Brian Christopher Investing, Trading Strategies, Winning Investor Daily Today, I want to talk about a few of the most popular investing tools … as well as a brand-new investment strategy that I believe deserves your attention.
If you don’t think the Wuhan coronavirus outbreak will impact the U.S. economy, I’ve got some bad news for you. The Chinese Time Bomb; Tesla Tendies Time February 4, 2020 by Joseph Hargett Great Stuff The Ticking Chinese Time Bomb Sorry to ruin your bull market party, but there’s an issue we need to discuss … like, right now. I’m talking about the Wuhan coronavirus and the U.S.-China “phase 1” trade deal. Here’s the thing: More than 20,000 Chinese are infected with the Wuhan virus, with some 427 dead. Tens […]
abbvie stock Profit From AbbVie’s Struggles Today February 4, 2020 by Chad Shoop American Investor Today, Stocks Abbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“I'm very Happy with your services. I hope you don't plan to retire any time soon! My retirement portfolio depends on your expert guidance. Keep up the great work! Thanks.”

- Randy

"I couldn’t believe it … in just 2 months, I made $298,506 on one stock – that’s a 24% gain!"

- John B.

"Since I started following your secret over your multiple publications, my $659,000 account is up to $715,000 in just 2 months. I’m up $56,000 in one month alone."

- Will O.

Share This